Expression of gonadotropin-releasing hormone receptor type-II correlates with proliferation activity in tissue microarray of rare ovarian tumor
Article Sidebar
Main Article Content
https://orcid.org/0000-0002-4466-1439
Ardhanu Kusumanto
https://orcid.org/0009-0001-7357-4633
Muhammad Ary Zucha
https://orcid.org/0000-0001-9337-8237
Nungki Anggorowati
https://orcid.org/0000-0002-3268-5492
Agil Wahyu Wicaksono
https://orcid.org/0009-0004-0003-7521
Moch Yunus
https://orcid.org/0009-0007-7593-4675
Erianto Fanani
https://orcid.org/0009-0006-3663-7048
Moh Mirza Nuryady
https://orcid.org/0000-0003-3193-1089
Abstract
Activation of Gonadotropin-Releasing Hormone type II Receptors (GnRHR-II) exhibits antiproliferative activity. GnRHR-II is not only expressed exclusively in the pituitary, but also in a variety of tumors. To date, the clinical relevance of GnRHR-II in ovarian tumors is unclear. In addition, there is a lack of literature addressing GnRHR-II in ovarian tumors, especially rare types. This study was conducted to investigare the correlation between GnRHR-II expression with clinicopathology and proliferative activity of rare ovarian tumors. The purpose of this study was an analytic observational study with a cross-sectional design that utilized 18 ovarian tumor samples on tissue microarray (TMA). The expression of GnRHR-II and Ki67 was assessed using immunohistochemical staining (IHC) and observed using the IHC profiler plugin ImageJ software to obtain their respective H-scores. The data was analyzed using independent t-test, ANOVA, Pearson's test, and Fisher's exact test based on data types. The value of p<0.05 was considered statistically significant. GnRHR-II is expressed in various forms in ovarian tumors, including extrapituitary expression. GnRHR-II expression was highest in the sex cord stromal tumor (SCST) group, 110.30 ± 23.89 (p<0.0001). In addition, there was also a significant difference between GnRHR-II expression with age (p<0.001) and the primary tumor (p<0.05), but not with tumor type (p=0.101). There is a correlation between GnRHR-II expression and proliferative activity (r=-0.043, p=0.866). Elevated GnRHR-II expression is significantly correlation with SCST, individuals over 40 years of age, and tumors confined to the ovary and it is correlates with lower proliferative activity, although this correlation is very weak.
Downloads
Article Details
Copyright (c) 2024 Kiky Martha Ariesaka, Ardhanu Kusumanto, Muhammad Ary Zucha, Nungki Anggorowati, Agil Wahyu Wicaksono, Moch Yunus, Erianto Fanani, Moh Mirza Nuryady
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Wang S, Jiang Y, Miao H, Fang Y, Jiang N, Yu Y, et al. Targeting rare tumors: new focus for clinical research in China. EMBO Mol Med. 2023;15(1):e16415. https://doi.org/10.15252/emmm.202216415
Mathoulin-Pélissier S, Pritchard-Jones K. Evidence-based data and rare cancers: The need for a new methodological approach in research and investigation. Eur J Surg Oncol. 2019;45(1):22–30. https://doi.org/10.1016/j.ejso.2018.02.015
Pinto MT, Eiras Martins G, Vieira AGS, Galvão JMS, de Pádua Souza C, Macedo CRPD, et al. Molecular biology of pediatric and adult ovarian germ cell tumors: A review. Cancers (Basel). 2023;15(11):2990. https://doi.org/10.3390/cancers15112990
Kaur H, Singh N, Bharti S, Kaur G. Exploring the unusual: a testosterone-secreting ovarian tumor. Autops Case Reports. 2024;14:e2024478. https://doi.org/10.4322%2Facr.2024.478
Ozenne A, De Berti M, Body G, Carcopino X, Graesslin O, Kerbage Y, et al. Risk factors for recurrence of borderline ovarian tumours after conservative surgery and impact on fertility: a multicentre study by the francogyn group. J Clin Med. 2022;11(13):3645. https://doi.org/10.3390/jcm11133645
Gründker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Cells. 2021;10(2):437. https://doi.org/10.3390%2Fcells10020437
Fontana F, Marzagalli M, Montagnani Marelli M, Raimondi M, Moretti RM, Limonta P. Gonadotropin-releasing hormone receptors in prostate cancer: molecular aspects and biological functions. Int J Mol Sci. 2020;21(24):9511. https://doi.org/10.3390/ijms21249511
Zucha MA, Dewanto A, Widad S, Taufiqurrachman I, Kusumanto A, Pangastuti N, et al. Expression of GnRH receptor type-ii correlates with proliferation activity in endometriosis. Int J Infertil Fetal Med. 2022;13(2):35–9. https://doi.org/10.5005/jp-journals-10016-1253
Dzulkifli FA, Mashor MY. An overview of recent counting methods for Ki67 IHC staining. J Biomed Clin Sci. 2018;3(2):10–7. https://myjurnal.mohe.gov.my/public/article-view.php?id=130450
Gründker C, Günthert AR, Millar RP, Emons G. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab. 2002;87(3):1427–30. https://doi.org/10.1210/jcem.87.3.8437
Magaki S, Hojat SA, Wei B, So A, Yong WH. An Introduction to the Performance of Immunohistochemistry. In: Methods Mol Biol. 2019. p. 289–98. https://doi.org/10.1007%2F978-1-4939-8935-5_25
Webb F, Morey A, Mahler-Hinder C, Georgousopoulou E, Koo R, Pati N, et al. Comprehensive FISH testing using FFPE tissue microarray of primary lymph node tissue identifies secondary cytogenetic abnormalities in Mantle Cell Lymphoma. Cancer Genet. 2023;274–275:75–83. https://doi.org/10.1016/j.cancergen.2023.04.002
Ruengwanichayakun P. Histochemical scoring assessment (H-score). Asian Arch Pathol. 2021;13(1):13–4. https://www.asianarchpath.com/view/152
Varghese F, Bukhari AB, Malhotra R, De A. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. Aziz SA, editor. PLoS One. 2014;9(5):e96801. https://doi.org/10.1371/journal.pone.0096801
Fanis P, Neocleous V, Papapetrou I, Phylactou LA, Skordis N. Gonadotropin-releasing hormone receptor (GnRHR) and hypogonadotropic hypogonadism. Int J Mol Sci. 2023;24(21):15965. https://doi.org/10.3390/ijms242115965
Valsamakis G, Valtetsiotis K, Charmandari E, Lambrinoudaki I, Vlahos NF. GnRH analogues as a Co-treatment to therapy in women of reproductive age with cancer and fertility preservation. Int J Mol Sci. 2022;23(4):2287. https://doi.org/10.3390/ijms23042287
Miller DS, Scambia G, Bondarenko I, Westermann AM, Oaknin A, Oza AM, et al. ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155). J Clin Oncol. 2018;36(15_suppl):5503–5503. https://doi.org/10.1200/JCO.2018.36.15_suppl.5503
Chen C-P, Lu X. Gonadotropin-releasing hormone receptor inhibits triple-negative breast cancer proliferation and metastasis. J Int Med Res. 2022;50(3):030006052210828. https://doi.org/10.1177%2F03000605221082895
Lu M, Zhu J, Ling Y, Shi W, Zhang C, Wu H. The lower expression of gonadotropin-releasing hormone receptor associated with poor prognosis in gastric cancer. Int J Clin Exp Med. 2015;8(8):13365–70. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612952/
Sultan Aldrees PZ. Gonadotropin-Releasing Hormone Receptor is expressed in Retinoblastoma. J Clin Exp Pathol. 2015;05(03). https://iovs.arvojournals.org/article.aspx?articleid=2336405
Kaur B. Pathology of malignant ovarian germ cell tumours. Diagnostic Histopathol. 2020;26(6):289–97. https://doi.org/10.1016/j.mpdhp.2020.03.006
Boussios S, Moschetta M, Zarkavelis G, Papadaki A, Kefas A, Tatsi K. Ovarian sex-cord stromal tumours and small cell tumours: Pathological, genetic and management aspects. Crit Rev Oncol Hematol. 2017;120:43–51 https://doi.org/10.1016/j.critrevonc.2017.10.007
Walkiewicz D, Wicik Z, Puzianowska-Kuznicka M. Gonadotropin-releasing hormone receptor pathway affects the function of human EBV-transformed B lymphocytes in an age-independent way. Exp Gerontol. 2021;152:111471. https://doi.org/10.1016/j.exger.2021.111471
Sun Y, Xu J, Jia X. The diagnosis, treatment, prognosis and molecular pathology of borderline ovarian tumors: Current status and perspectives. Cancer Manag Res. 2020;12:3651–9. https://doi.org/10.2147%2FCMAR.S250394
Suo L, Chang X, Xu N, Ji H. The anti-proliferative activity of GnRH through downregulation of the Akt/ERK pathways in pancreatic cancer. Front Endocrinol (Lausanne). 2019;10:370. https://doi.org/10.3389/fendo.2019.00370
Montagnani Marelli M, Moretti RM, Mai S, Januszkiewicz-Caulier J, Motta M, Limonta P. Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells. J Clin Endocrinol Metab. 2009;94(5):1761–7. https://doi.org/10.1210/jc.2008-1741
